Discover

Back to filter

Related topics

Advances in Leukemia research using shear flow and Bioflux system

Fluxion Biosciences

May 24, 2022

Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...

In-vivo webinar: a versatile use of SPECT/CT in the development of theranostic tracers

MOLECUBES

Mar 9, 2022

Combining (preclinical) imaging and targeted therapy, is the basis of theranostics. In this webinar, Dr. Florea will...

WEBINAR: Recent Advancements In Neurodegenerative Biomarkers

Quanterix

Sep 6, 2021

Recent Advancements in Neurodegenerative Biomarkers: Progress Towards a Diagnostic Blood Test for Alzheimer’s Disease

Recorded Webinar – the basics of Intravital Fluorescence Microscopy

IVIM Technology

Aug 6, 2021

This is the first of a 4-part series introducing Scintica’s newly formed relationship...

Webinar recording: Autofluorescence management - the power of Spectral Flow Cytometry

Cytek Biosciences

Jul 15, 2021

One of the key advantages of spectral flow cytometry is its ability to extract sample...

Webinar recording: Super-Resolution imaging of Chromatin organization in health and disease

ONI

Jul 9, 2021

Understanding how cells organize the array of components within their membranous confines can not only provide insight...

Show all topics (10)

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

Aug 21, 2017

September 7, 2017, 7 pm CEST

Chia-Wei Li, PhD, The University of Texas M. D. Anderson Cancer Center 

Here we reveal PD-L1’s immunosuppression activity is stringently modulated by the spatial restraints between ubiquitination and N-linked glycosylation. We identified GSK3beta as a novel PD-L1 interacting protein capable of inducing phosphorylation dependent proteasome degradation. The essence of PD-L1 N192, N200 and N219 glycosylation suggests it antagonizes GSK3beta binding. In this regard, only non-glycosylated PD-L1 forms a complex with GSK3beta and beta-TrCP. More importantly, activation of GSK3beta-mediated PD-L1 degradation by TKI can reduce membrane PD-L1 expression and thereby enhance anti-tumor immunity. To test T cell-mediated cancer cell killing in vitro, we employed a time lapse microscopy, IncuCyte, to monitor RFP-tagged BT549 cells and activated PBMC interaction over a five day period. Massive cancer cell death was observed in glycosylation deficient cancer cells, suggesting glycosylation of PD-L1 is required for its immunosuppression. Together, our results link ubiquitination and glycosylation pathways with stringent regulation of PD-L1, proposing a new therapeutic strategy to enhance cancer immune therapy efficacy.

Learning objectives:

  • Molecular mechanism of PD-L1 regulation in cancer cells
  • Immunosuppressive nature of triple negative breast cancer
  • Using in vitro co-culture system to analyze T cell-mediated cancer cell killing effect

Register now

Webinar

Related technologies: BioImaging

Brand profile

Sartorius

Essen BioScience (part of Sartorius), is a team of engineers and biologists with deep expertise in cell-based assays. They invent, manufacture, supply and support cell-based assay instrumentation, reagents and protocols.

Related products

High throughput, real-time and automated measurements of live-cell activity, inside your incubator

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey